/
DTIL
$7.20-$0.12 (-1.62%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$204.8M
28M shares
52-week range
$3.53 – $9.62
60% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-277.70
Precision BioSciences, Inc. Common Stock
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
www.precisionbiosciences.com- Employees
- 67
- IPO / List date
- Mar 28, 2019
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds DTIL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 223,177 | $1.2M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-14 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded DTIL yet.
